Selling a Dental Practice: DSO Acquisitions, Tax Strategy, and Valuation (2026)

Dental practice M&A is one of the most active segments in U.S. lower-middle-market deal flow, driven by aggressive DSO consolidation and a historic wave of boomer-era practice transitions. But the tax traps are significant — and the typical dental practice broker does not model them. Here is what the exit planning actually looks like.

Dental practice M&A landscape in 2026

The dental practice acquisition market in 2026 is heavily DSO-driven. A 2026 industry survey found that 69% of DSOs plan to meaningfully increase their acquisition activity, and more than 1,000 Invisible Dental Support Organizations (IDSOs) are now actively seeking majority-stake partnerships.³ For most practice owners with $1M+ in annual collections, a DSO or IDSO transaction is the most likely exit path — and it produces the most complex tax consequences.

Buyer types

Four distinct buyer categories exist in the dental market, each with materially different deal structures, valuation metrics, and tax implications for the seller:

Valuation: collections multiples vs. EBITDA multiples

Dental practices are valued using two methodologies depending on buyer type — collections-based for smaller practices and dentist buyers, EBITDA-based for DSO buyers above a certain threshold.

Collections-based valuation (smaller practices and dentist buyers)

For practices under $1M EBITDA, particularly those sold to individual dentist buyers, collections multiples remain the dominant shorthand:

• General dentistry: 65–85% of trailing 12-month gross collections
• Specialty practices (orthodontics, oral surgery, periodontics, pediatric): 75–110% of T12M collections

Collections multiples are blunt instruments. A practice with $1.2M in collections and 40% EBITDA margin is worth far more per dollar of collections than one running 20% margin. When EBITDA margin diverges significantly from the 30–35% range typical of well-run general practices, collections multiples give a misleading answer.

EBITDA multiples (DSO and IDSO buyers)

DSOs price acquisitions on adjusted EBITDA — revenue minus expenses, adding back the owner-dentist's above-market compensation and one-time items. A quality-of-earnings normalization is standard for any DSO deal above $1M EBITDA.⁴

What drives valuation in DSO deals

DSOs in 2026 are prioritizing practices with the following characteristics over raw collections volume:

• Hygiene revenue above 30% of total production. Hygiene revenue is highly recurring, less dependent on the owner-dentist, and signals patient retention. Practices with strong hygiene programs command premium multiples.
• Associate-led production. A practice where associates produce 40%+ of revenue has enterprise value that survives the selling dentist's departure. A practice 100% dependent on the owner is effectively just the present value of the owner's continued employment.
• Multi-location operations. Regional groups with 3+ locations trade at significant premiums to single-location practices because they offer an established infrastructure DSOs can plug into without building from scratch.
• Payer mix. Practices with commercial PPO or fee-for-service revenue mix command higher multiples than Medicaid-heavy practices.

QSBS: the exclusion dentists cannot use

IRC §1202 allows qualified small business stockholders to exclude up to $15M in capital gain (post-OBBBA) when selling C-corporation stock held for 5+ years. It is arguably the single most powerful tax planning tool available for business owners — but it is completely unavailable to dental practice owners.

Section 1202(e)(3)(A) explicitly excludes any trade or business "in the field of health" from qualified small business status.¹ Dental services are the delivery of health care — patient examination, diagnosis, and treatment — which falls squarely within the health exclusion. There is no structure, election, or entity conversion that enables a dental practice to qualify for §1202. Every dollar of gain from selling a dental practice is subject to full capital gains tax (or ordinary income tax, depending on asset class). This makes the allocation and personal goodwill strategies discussed below materially more important for dental sellers than for sellers in eligible industries.

The four-layer dental tax stack

When a dental practice is sold via asset sale (the default for most transactions), the purchase price is allocated across multiple asset classes under IRC §1060 and reported on Form 8594. Each class carries a different federal tax rate for the seller:

Worked example: $3M dental asset sale

Consider a general dentist selling a $3M S-corp practice. The allocation negotiated at closing matters enormously:

Now shift $550K from non-compete to goodwill — a negotiation that is buyer-neutral (both are §197 intangibles amortized over 15 years, so the buyer's deduction stream is identical regardless of class):

Savings: $73,000 in federal tax from the same $3M sale price. In practice, buyers sometimes push for a larger non-compete allocation because it does not change their economics — sellers who do not have a tax advisor at the negotiating table often accept it without understanding the cost.

Personal goodwill: the primary tax lever

In dental practices, a substantial portion of the patient base, the clinical reputation, and the referral relationships belong to the dentist personally — not to the corporate entity. This matters for tax in two distinct ways depending on your entity type.

For S-corp and LLC dental practices (the majority)

S-corps and LLCs are already pass-through entities, so there is no double-taxation risk on goodwill. But the personal goodwill doctrine still affects the character of income. If the dentist can document that the bulk of goodwill is personal — based on patient relationships, clinical reputation, and referral network belonging to the individual — that goodwill is properly characterized as §1231 capital gain at the individual level at 23.8%, rather than as employment compensation or consulting income at 37%.

Key documentation requirements for personal goodwill in dental:

• Demonstrate that patients follow the dentist, not the practice brand (patient retention analysis)
• Employment history showing the dentist was not bound by a prior non-compete or other agreement that transferred goodwill to the entity
• No prior transaction (e.g., dental partnership agreement) that conveyed personal goodwill to the entity
• Allocation in the purchase agreement between personal goodwill and practice goodwill, documented separately

For C-corp dental practices

C-corps face a double-tax problem on asset sales: the entity pays 21% on any gain, and the shareholder then pays LTCG rates on the distribution. On a $3M practice, the combined effective rate on entity-level goodwill can reach 39–40%. The personal goodwill argument removes that gain from the C-corp — the dentist is selling their personal intangible directly to the buyer, bypassing the corporation — and brings the effective rate down to 23.8%. This is the same Martin Ice Cream doctrine applied to dental practices that we cover in our personal goodwill guide. Successful C-corp personal goodwill arguments require careful documentation and ideally should be set up well before a sale.

For most dentists operating as S-corps or LLCs, the C-corp double-tax scenario does not apply — but the personal goodwill vs. non-compete allocation negotiation remains highly valuable.

DSO deal structure: cash, rollover equity, and earnout

A DSO acquisition of a dental practice typically has three components: upfront cash, rollover equity in the DSO, and an earnout based on future performance. Each is taxed differently.

Upfront cash at closing

This is the clean portion — typically 60–80% of total deal value in a DSO transaction. The tax treatment is governed by the asset class allocation on Form 8594. Most DSO acquisitions structure this as an asset purchase (not a stock sale), so the allocation mechanics described above apply. Goodwill allocated here is taxed at 23.8%; equipment and non-compete at 37%.

Rollover equity in the DSO

Most DSO transactions include a rollover component — the seller contributes a portion of the sale proceeds (or the DSO retains a portion on the seller's behalf) as equity in the acquiring DSO entity. This rollover defers the gain on that portion under §351 (for C-corp contributions) or §721 (for partnership/LLC contributions). See our PE rollover equity guide for the full mechanics.

The rollover creates the "second bite" — when the DSO itself is eventually acquired or recapitalized (often within 3–7 years at DSO platforms), the dentist receives proceeds on the rolled equity. If the DSO has grown, that second bite can be worth significantly more than the original rollover. The second bite is typically taxed as LTCG if held long enough, but the exact treatment depends on how the equity was structured and how the DSO exit is structured.

QSBS on rollover equity?

An important exception: if the acquiring DSO is itself a C-corporation that qualifies as a QSBS issuer — meaning it is not itself a "health field" business at the DSO level (it is arguably a management/support company, not a health services provider) — the rolled equity may qualify for §1202 treatment. This is a contested area of tax law and requires a written opinion from a qualified tax attorney, but it has been used in DSO transactions where the acquiree's operating entity is the clinical practice (excluded) and the DSO holding company is the management platform (potentially not excluded). Do not rely on this without specific legal advice.⁵

IDSO: the hands-off majority-stake model

Invisible Dental Support Organizations (IDSOs) differ from traditional DSOs in one important way: they acquire a majority stake (typically 51–80%) without rebranding the practice, changing clinical workflow, or requiring the selling dentist to report to a regional manager. More than 1,000 IDSOs operate in the U.S. as of 2026, many backed by family offices or strategic investors rather than private equity — which means no fund clock and no forced 5-year exit timeline.⁶

Tax treatment of an IDSO majority-stake sale

When a dentist sells 60% of their practice to an IDSO for $3M (in a $5M-valued practice), the structure is typically:

• $3M cash at closing: Taxed according to asset-class allocation (same mechanics as above — goodwill at 23.8%, equipment at OI, non-compete at OI).
• 40% equity retained: No taxable event at the time of sale. Basis carries over.
• Future liquidity: When the IDSO recapitalizes or is acquired, the retained 40% generates a second liquidity event taxed at LTCG rates (if the dentist holds equity long enough for long-term treatment).

The IDSO structure generally produces a cleaner tax result than a traditional DSO deal with earnout because there is no ongoing production-linked payment to be recharacterized as compensation.

The earnout ordinary income trap

Many DSO deals include an earnout component — a payment made 1–3 years after closing, contingent on the practice hitting production or collections targets during the period the selling dentist remains as an employed associate. This is where dental deal taxation gets complicated.

Under IRC §453 and decades of case law, the IRS looks beyond how the parties label a payment. If an earnout payment is:

• Tied to the selling dentist's individual production (rather than the practice's overall results), and
• The dentist must remain employed to receive it,

the IRS is likely to characterize the payment as deferred compensation — ordinary income subject to 37% plus employment taxes — not capital gain.⁷

Earnout payments tied to practice-wide EBITDA or collections (not to the individual dentist's chair production specifically) are in a better position for capital gain treatment. The structure of the employment agreement matters: if the earnout period exactly matches the employment term and the earnout payout scales dollar-for-dollar with the dentist's chair time, that correlation is hard to defend as anything other than compensation.

Practical implication: Before accepting a DSO term sheet with an earnout, have a tax attorney review whether the earnout structure supports capital gain treatment. A seemingly small structural change — tying the earnout to practice-level cash flow rather than the dentist's individual production — can preserve LTCG treatment and be worth tens of thousands of dollars.

Dentist-to-dentist sale: SBA 7(a) mechanics

For smaller practices (under $5M sale price), the most common buyer is another dentist — typically a recent graduate or associate — financed through an SBA 7(a) loan. This creates a different set of deal mechanics from DSO transactions.

SBA 7(a) basics for dental acquisitions

• Loan cap: $5M. Dental practice acquisitions are among the cleanest SBA-eligible transactions because the cash flows are predictable and lenders have deep underwriting experience with dental.
• Terms: 10-year amortization for goodwill and equipment; 25-year for real estate; floating rate at Prime + 2.5–3% (approximately 9.75–10.25% APR in 2026).⁸
• Buyer equity required: Typically 10% of purchase price.
• Asset sale required: The SBA requires asset purchases rather than stock sales for the loan to be eligible. This means the buyer gets a stepped-up basis, and the seller faces asset-class allocation — same as any other dental asset sale.

Seller note in SBA-financed deals

SBA lenders often require a seller note of 10–20% of the purchase price, structured on full standby (no principal or interest payments) for the first 24 months. This is SBA SOP 50 10 8 standby requirement — the seller note must be fully subordinated with no payments until the senior SBA debt is comfortably serviced. See our seller financing guide and SBA loan impact guide for full details.

From the seller's tax perspective, a seller note creates an installment sale under §453 — the gain is recognized as payments are received rather than all in year one. This can defer taxes into future years when the seller may have lower income. The §453A interest charge (6% on the deferred tax liability when notes exceed $5M outstanding) is not typically relevant for dental practice sales since most deals are under $5M total.

Associate buy-in as an exit alternative

A full sale is not the only exit path. Dentists who want to reduce risk, transition gradually, or pass the practice to a trusted associate often structure a phased buy-in instead. Common structures include:

• Minority stake sale (25–49%): Sell a minority stake to an associate over 1–3 years, funded through practice cash flows. The associate builds equity; the owner dentist retains control while reducing personal concentration risk.
• Earn-in arrangement: The associate earns equity over time based on production milestones, without an upfront cash payment. This is operationally flexible but creates ongoing tax complexity — gain is recognized as each equity tranche vests.
• Buy-sell agreement: A formal agreement setting the price and terms under which the associate will purchase the remaining equity at a specified future date or upon the owner's retirement or death. See our buy-sell agreement guide for valuation methodology and funding mechanics.

Associate buy-ins generally produce lower overall sale prices than DSO transactions — DSOs pay a significant premium for the platform value. But they eliminate rollover equity complexity, earnout risk, and the obligation to continue practicing under a corporate employment agreement for 2–5 years post-close.

State tax considerations

Federal tax is only part of the picture. State tax can materially change the after-tax math, particularly for practices in high-rate states:

• California: 13.3% marginal rate on all income, including capital gains. California does not conform to the federal preferential cap gains rate — all gain is taxed as ordinary income at state level. A $3M dental practice sale in California adds $400K in state tax versus the same sale in Florida or Texas. California's Franchise Tax Board also aggressively audits residency changes made shortly before a sale — see our state residency guide for the 546-day safe harbor analysis.
• New York: Up to 14.8% combined state + NYC rate on capital gains for NYC residents; 9.65% at the state level outside NYC.
• New Jersey: 10.75% on income above $1M (capital gains treated as ordinary income for state purposes).
• No-income-tax states (Florida, Texas, Nevada, Washington): No state capital gains or income tax on practice sale proceeds. Washington's capital gains tax applies but has a $250K exemption and a "small business" exclusion — see your advisor for Washington specifics.

For dentists planning a sale 2+ years out and currently in a high-tax state, establishing domicile in a no-income-tax state before closing is a legitimate strategy — but it requires genuine intent to change residence, not a paper move, and early coordination with a tax attorney.

Planning timeline: 2–5 years before sale

The most common dental practice sale mistake is engaging an advisor only after a DSO sends an LOI. By then, the highest-value planning windows are closed. Here is what the ideal timeline looks like:

What an advisor models before you sign

A fee-only financial advisor specializing in business exits models the dental practice sale from both sides of the equation before you sign anything:

• Pre-sale: Entity structure review; personal goodwill documentation strategy; estimated post-close tax bill under multiple allocation scenarios; comparison of DSO cash offer vs. IDSO majority-stake structure vs. dentist-to-dentist SBA sale; state residency analysis if applicable.
• Deal structure: Earnout characterization risk analysis; rollover equity valuation and second-bite scenarios; installment note vs. lump-sum comparison at your expected post-close income; employment agreement compensation structure and its tax implications.
• Post-sale: Estimated quarterly tax payments for year of sale (safe harbor requires paying 110% of prior-year AGI if over $150K); Roth conversion window in the years following when ordinary income drops; portfolio construction from concentrated practice equity to diversified investments; estate planning reset with proceeds.

Investment bankers optimize for deal-close price. M&A attorneys optimize for legal structure. Dental practice brokers optimize for commission. None of them models the financial-plan consequences of deal structure — that is the exit-planning financial advisor's role.